Abstract
Background Immune checkpoint receptors regulate adaptive immunity but are increasingly recognized as modulators of neuroimmune interactions. The upstream signals that induce neuronal checkpoint pathways during inflammation and their functional relevance in inflammatory pain remain incompletely understood. We investigated whether a defined commensal-derived molecule engages a neuroimmune checkpoint axis to modulate inflammatory pain.
Methods
SELTA, a lipoteichoic acid purified from a commensal Staphylococcus epidermidis strain, was evaluated for TLR2-dependent activity, regulation of Pdcd1 transcription and PD-1 protein expression in dorsal root ganglion (DRG) neurons, effects on intracellular calcium signaling, and behavioral outcomes in experimental autoimmune prostatitis (EAP) a model of inflammation-induced chronic pelvic pain. Conditional Pdcd1 deletion was performed in sensory neurons (Advillin-Cre) and CD4⁺ T cells to determine cell-specific requirements.
Results
SELTA selectively activated TLR2/6 signaling and increased Pdcd1 transcription and PD-1 protein expression in DRG neurons under inflammatory conditions. SELTA enhanced phosphorylation of PD-1 at tyrosine 248 and significantly reduced ATP-evoked intracellular Ca²⁺ responses in mouse primary sensory neurons. Pharmacologic neutralization of PD-1 abrogated SELTA-mediated suppression of calcium signaling. In vivo, SELTA produced concentration-dependent attenuation of pelvic hypersensitivity in EAP. Conditional deletion of PD-1 in vivo in Advillin-expressing sensory neurons or CD4⁺ T cells significantly reduced SELTA-induced analgesia, while combined deletion did not further diminish the effect.
Conclusions
These findings identify a commensal-derived lipoteichoic acid that engages a TLR2/6-associated pathway linked to inducible neuronal PD-1 signaling to restrain inflammatory nociceptor activity. The results define a neuroimmune checkpoint mechanism that modulates inflammatory pain and extend PD-1 signaling beyond its established role in adaptive immunity.
Competing Interest Statement
Dr. Praveen Thumbikat and Dr. Anthony J. Schaeffer are inventors on a Northwestern University- owned patent related to the SELTA molecule described in this manuscript. Both authors are co-founders of Equilibrio Biosciences Inc., a startup company interested in SELTA-based therapeutic development. These interests did not influence the design, conduct, or interpretation of the study. All other authors declare no competing interests.
Footnotes
This version of the manuscript has been modified to include additional data in the main manuscript as well as in supplementary figures. Sections of the manuscript, including the Title, abstract, results and discussion have been modified.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.